MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Omeros Corp

Затворен

СекторЗдравеопазване

3.66 6.09

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.64

Максимум

3.72

Ключови измерители

By Trading Economics

Приходи

-2.1M

-33M

Продажби

412K

412K

Марж на печалбата

-8,121.359

Служители

202

EBITDA

-1.9M

-35M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+146.58% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-235M

187M

Предишно отваряне

-2.43

Предишно затваряне

3.66

Настроения в новините

By Acuity

30%

70%

65 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Omeros Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.07.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

FCC Approves U.S. Cellular Sale to T-Mobile

11.07.2025 г., 17:28 ч. UTC

Значими двигатели на пазара

SharpLink Gaming Gains on Ethereum Purchase

11.07.2025 г., 16:57 ч. UTC

Печалби

BASF Cuts Outlook on Global Economy Uncertainty

12.07.2025 г., 17:01 ч. UTC

Печалби

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12.07.2025 г., 14:53 ч. UTC

Печалби

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

12.07.2025 г., 02:24 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12.07.2025 г., 02:05 ч. UTC

Придобивния, сливания и поглъщания

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11.07.2025 г., 21:45 ч. UTC

Пазарно говорене

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11.07.2025 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11.07.2025 г., 19:45 ч. UTC

Пазарно говорене

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11.07.2025 г., 19:05 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11.07.2025 г., 18:18 ч. UTC

Пазарно говорене

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11.07.2025 г., 17:35 ч. UTC

Пазарно говорене

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11.07.2025 г., 17:26 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11.07.2025 г., 16:53 ч. UTC

Пазарно говорене

Crude Futures Add to Early Gains -- Market Talk

11.07.2025 г., 16:42 ч. UTC

Печалби

BASF Cuts Outlook on Global Economic Uncertainty

11.07.2025 г., 16:08 ч. UTC

Пазарно говорене

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11.07.2025 г., 16:05 ч. UTC

Печалби

BASF Will Publish Half-Year Results on July 30

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

11.07.2025 г., 16:04 ч. UTC

Пазарно говорене

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11.07.2025 г., 16:03 ч. UTC

Печалби

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11.07.2025 г., 16:02 ч. UTC

Печалби

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11.07.2025 г., 16:01 ч. UTC

Печалби

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11.07.2025 г., 16:00 ч. UTC

Печалби

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11.07.2025 г., 15:59 ч. UTC

Печалби

BASF Cuts 2025 Earnings View

11.07.2025 г., 15:58 ч. UTC

Печалби

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11.07.2025 г., 15:57 ч. UTC

Печалби

BASF 2Q EBIT Before Special Items EUR810M

11.07.2025 г., 15:54 ч. UTC

Печалби

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Ценова цел

By TipRanks

146.58% нагоре

12-месечна прогноза

Среден 9 USD  146.58%

Висок 9 USD

Нисък 9 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Omeros Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

6.265 / 7.49Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

65 / 376 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.